Search
Close this search box.

Category: English

Decisive action needed to achieve net zero by 2050, as world is currently on path for 2.5 ˚C to 3 ˚C global warming, according to Wood Mackenzie

Analysis shows US$78 trillion needed to achieve net zero and 1.5 C warming scenario Wood Mackenzie Energy Transition Outlook 2024/2025 LONDON and HOUSTON and SINGAPORE, Oct. 29, 2024 (GLOBE NEWSWIRE) — A string of global shocks has likely put 2030 emissions reduction targets out of reach. But with decisive action, there is still time to […]

Read More

Mavenir Welcomes O-RAN ALLIANCE Report for Spectrum Aggregation in Multi-Vendor Deployments

New technical report – initiated and led by Mavenir – evaluates an open interface specification support between DUs for carrier aggregation in multi-vendor deployments RICHARDSON, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) — Mavenir, the cloud-native network infrastructure provider building the future of networks, today welcomes the publication of a new Technical Report by the O-RAN […]

Read More

2ONE Labs Receives PMTA ‘Acceptance’ for 2ONE® Nicotine Pouch brand from FDA Center for Tobacco Products

LAKE TAHOE, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) — 2ONE Labs Inc., is pleased to announce the ‘Acceptance’ of its Premarket Tobacco Product Application (PMTA) submission by the U.S. Food and Drug Administration for its 2ONE® branded nicotine pouches. Acknowledging receipt of the FDA ‘Acceptance’ notification, Vincent Schuman, CEO of 2ONE Labs, said: “This means the 2ONE® PMTA […]

Read More

Quantexa Reaches Centaur Status, Surpassing $100 Million ARR

Quantexa’s strong innovation pipeline, global presence and go-to-market strategy set the stage for continued growth, supporting its expanding customer base in building trusted data foundations for AI LONDON, Oct. 29, 2024 (GLOBE NEWSWIRE) — Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced today that it has surpassed $100 […]

Read More

2ONE® Nicotine Pouches Joins MBM Motorsports in Multi-Race Sponsorship

Josh Bilicki and Chad Finchum will each get a start in the 2ONE Pouches No. 66 NASCAR Cup Series entry STATESVILLE, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) — Motorsports Business Management (MBM Motorsports) has signed 2ONE® Nicotine Pouches (“Twenty-One”) to a multi-race sponsorship deal to conclude the 2024 NASCAR Cup Series championship. The No. 66 […]

Read More

Examined: Artificial Intelligence Redefining Marketing in 2024 – From Generic Ads to Tailor-made Experiences

WATERFORD, Ireland, Oct. 24, 2024 (GLOBE NEWSWIRE) — Marketing in 2024 is being redefined by artificial intelligence (AI) and machine learning (ML). It has already turned traditional marketing on its head, making generic adverts a thing of the past. Now, it’s all about data-driven precision and delivering tailor-made experiences that resonate with audiences. For the […]

Read More

2024 Business School Applications Skyrocket amidst Economic Uncertainty

GMAC’s annual survey shows demand growth is five times greater than the pandemic boom RESTON, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) — Across the globe, total applications to graduate business school programs in 2024 increased an impressive 12 percent from 2023 to 2024. This is a sharp reversal from the previous two consecutive years of […]

Read More

EBC Financial Group and the University of Oxford’s Department of Economics Announce WERD Episode on Macroeconomics and Climate

Balancing Economic Growth and Climate Resilience: A Global Discussion OXFORD, United Kingdom, Oct. 23, 2024 (GLOBE NEWSWIRE) — EBC Financial Group (EBC) is proud to announce its continued collaboration with the University of Oxford’s Department of Economics for the 2024-2025 edition of the acclaimed “What Economists Really Do” (WERD) webinar series. The upcoming event will be the […]

Read More

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each […]

Read More